Paragon 28

Paragon 28 Gross Margin

Delisted

The Gross Margin of Paragon 28 (FNA) as of Nov 4, 2026 is 74.75 %. In the previous year, Gross Margin was 72.67 % — a change of 2.86% (higher).

Gross Margin

74.75 %

YoY

2.86%

Last updated:

Gross Margin of Paragon 28 is 2024 74.75 % . Gross Margin of Paragon 28 was 2023 72.67 % . It decreases by 2.86% higher compared to the previous year.

For Paragon 28, the gross margin of 78.3% is broadly stable versus 78.2% a few years ago.

The Paragon 28 Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
82.28 USD
Jan 1, 2020
77.38 USD
Jan 1, 2021
81.00 USD
Jan 1, 2022
82.11 USD
Jan 1, 2023
72.67 USD
Jan 1, 2024
74.75 USD
The Paragon 28 Gross Margin history
YEARGross MarginYoY
74.75 %+2.86%
72.67 %-11.49%
82.11 %+1.37%
81.00 %+4.67%
77.38 %-5.95%
82.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Paragon 28 Stock analysis

What does Paragon 28 do? Paragon 28, Inc. generates revenue through the development, distribution, and sale of medical devices in the foot and ankle orthopedic implant market. The company offers a comprehensive portfolio including plates and plating systems, screws, staples, and nails for fracture fixation, bunion and hammertoe procedures, ankle treatments, flatfoot correction, and Charcot foot solutions. Its surgical solutions consist of 75 product systems with approximately 9,200 SKUs, comprising 6,800 implants, 1,400 instruments, and 1,000 disposables. Hospitals and orthopedic surgeons purchase these products for patient care and surgical procedures. The company’s product families address all foot and ankle procedures, including progressive collapsing foot deformity (PCDF) and orthobiologics. Surgical implants, disposables, and instrumentation are sold directly to healthcare providers. The firm’s focus on specialized foot and ankle solutions allows it to serve a niche segment within the orthopedic implant marketplace. Paragon 28’s portfolio includes approximately 6,800 implants, 1,400 instruments, and 1,000 disposable SKUs, providing tailored options for diverse surgical needs. Paragon 28, Inc. operates within the orthopedic implant industry, targeting hospitals and surgical centers specializing in foot and ankle care. Its products are designed for specific anatomical and surgical requirements, with sizes and configurations varying to fit individual patient needs. The company’s revenue is derived from the sale of its extensive product range, including surgical implants, disposables, and instrumentation, to healthcare providers who perform foot and ankle procedures. Paragon 28 is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Paragon 28 stock

Gross Margin of Paragon 28 is 74.75 % in 2024.

Gross Margin of Paragon 28 changed from 72.67 % to 74.75 %, representing a 2.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Paragon 28 since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Paragon 28 with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Paragon 28

All Key Metrics — Paragon 28